Pathological bacterial translocation in liver cirrhosis.
By R. Wiest, Melissa A. E. Lawson, M. Geuking. Journal of Hepatology, 2014
749 citations recorded by the source corpus.
Humans harbor nearly 100 trillion intestinal bacteria, which in terms of numbers, represents around ten times more microbial cells than eukaryotic cells. The gastrointestinal (GI) tract, the largest surface area of the body with an epithelial surface of approximately 400 m, is in constant exposure to these live microorganisms. Their peaceful coexistence demonstrated by the lack of pro-inflammatory responses against commensal bacteria implicates the presence of clearly defined lines of communication. In fact, bacterial translocation (BT), being defined as translocation of bacteria and/or bacterial products (lipopolysaccharides, peptidoglycans, muramyl-dipeptides, bacterial DNA, etc.) from the gut to mesenteric lymph nodes (MLN) [1], is a physiological process in healthy conditions and crucial for host immunity. In contrast, in cirrhosis ‘‘pathological’’ BT develops with a sustained increase in quantity (rate and/or degree) of BT. However, at least in humans, lack of access to MLN and/or upstream compartments towards the mucosal barrier until now hamper establishment of ‘‘cut-off’’ levels for physiological levels of BT in individual patients. Nonetheless, there appears to exist a hierarchy of three barriers against pathological BT, each of which encompasses a distinct set of mechanisms (Fig. 1). First, there are mediators that limit direct contact between the intestinal bacteria and the epithelial cell surface. Secondly, a layer of immune protection involves the rapid detection and killing of bacteria that manage to penetrate. Finally, a set of immune responses minimizes exposure of bacteria to the systemic immune system. In advanced liver cirrhosis, at each of these
Subfields: Epidemiology, Hepatology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/e1cc12594fe6a33c6bb2b5e82c32fdb21e15b147
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
- P. Ginés
- M. Bernardi
- P. Angeli
- W. Laleman
- J. Trebicka
- Rajeshwar P. Mookerjee
- G. Garcia‐Tsao
- Aleksander Krag
Citations in the corpus
- Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. (2014, background): “Specifically, cirrhosis leads to increased intestinal permeability, due to compromised epithelial integrity, intestinal bacterial overgrowth and dysbiosis, caused by disruption of host microbiota homeostasis and intestinal and general immune defence impairment [97,98].”
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. (2018, background): “The new theory is that the increased circulating levels of pro-inflammatory cytokines and chemokines [340,341] may exercise a direct relevant role in the development of HRS.”
- Acute-on chronic liver failure. (2012, background): “Translocation of PAMPs in the absence of infection is a well recognized feature in patients with advanced cirrhosis related to intestinal hypomotility and bacterial overgrowth, increased mucosal permeability and impaired intestinal immune system function [14].”